Single-use Bioprocessing Market Size to Increase USD 128.24 Bn by 2033

According to Nova One Advisor, the global single-use bioprocessing market size was estimated at USD 28.45 billion in 2023 and it is projected to increase USD 128.24 billion by 2033 with a CAGR of 16.25% from 2024 to 2033.

Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.novaoneadvisor.com/report/sample/5765

The demand for single-use bioprocessing offerings is driven by the commercial advantages offered, including a reduction in costs and time required for bioprocessing operations. Originally used for monoclonal antibody production, single-use technologies are also gaining traction for cell and gene therapy manufacturing. As a result, broadening the scope of applications in biomanufacturing operations is likely to drive industry growth.

Furthermore, strategic initiatives from key players are expanding the industry’s growth prospects. For instance, in July 2021, Cytiva and Pall Corp. announced investment plans for capacity expansion over two years. Among other key products, more than USD 300 million were invested in single-use technologies, such as bioreactor bags for cell expansion, used to make personalized therapies and syringe filters for scientific research. Similarly, the growing adoption of single-use equipment for in-house and contract manufacturing has opened new avenues for the flow of investments in this space. The industry is witnessing significant advancements in several product portfolios, including disposable probes and sensors, stirring systems, bioreactor designs, and filtration technologies, which are expected to contribute to strong revenue growth.

The benefits offered by single-use bioprocessing systems have enabled biopharmaceutical manufacturers to offer their products faster to the market by introducing multi-product facilities, entering into partnerships, or outsourcing pipeline products for contract development and manufacturing. For instance, in January 2021, Sartorius AG partnered with RoosterBio, a leading supplier of human Mesenchymal Stem/Stromal Cells (hMSC). This collaboration aimed at advancing cell & gene therapy manufacturing by leveraging the single-use manufacturing technologies from Sartorius AG. The COVID-19 pandemic has generated new growth opportunities for key stakeholders in the industry.

Key biopharmaceutical players can leverage the opportunity by expanding their COVID-19-related product offerings by scaling up their production facilities with the implementation of single-use bioprocessing equipment. A significant number of biopharmaceutical companies are actively involved in the development and production of COVID-19 vaccines. These programs are majorly based on single-use technologies as these systems are flexible, cost-effective, and reduce the risk of cross-contamination. Such an ongoing and continuous increase in the adoption of bioprocessing systems due to the COVID-19 pandemic is anticipated to drive industry growth.

Key Takeaways:

• North America held the largest revenue share of more than 34.45% in 2023.
• The Asia Pacific region is expected to grow at the fastest rate over the forecast period.
• The simple & peripheral elements segment recorded the largest market share of 49.61% in 2023.
• The apparatus & plants segment is projected to grow at a rapid CAGR over the forecast period.
• The upstream bioprocessing segment held the largest market share in 2023.
• The fermentation segment is expected to register significant CAGR over the forecast period.
• Biopharmaceutical manufacturers dominated the market and accounted for the highest share in 2023.
• Academic & clinical research institutes are expected to grow at the fastest CAGR during 2024-2033.

Single-use Bioprocessing Market Top Trends

• Rising demand for biopharmaceuticals: The biopharmaceutical industry is booming, with increasing demand for drugs like monoclonal antibodies and vaccines. Single-use bioprocessing systems offer a faster and more efficient way to manufacture these drugs, which is helping to meet this demand.
• Reduced risk of contamination: Traditional bioprocessing equipment can be difficult to clean and disinfect, which can lead to cross-contamination between batches. Single-use systems eliminate this risk, as the disposables are discarded after each use.
• Lower costs: Single-use systems can help to reduce overall bioprocessing costs by eliminating the need for cleaning and validation of reusable equipment. They can also help to reduce facility footprint requirements.
• Faster turnaround times: Single-use systems can help to speed up the bioprocessing timeline, as there is no need for cleaning and validation between batches. This can be critical for getting new drugs to market faster.
• Focus on sustainability: Single-use systems can help to reduce water usage and waste generation in bioprocessing facilities. Some manufacturers are also developing biocompatible and biodegradable materials for single-use products, which can further improve the sustainability profile of this technology.

Here are some additional trends that are expected to impact the single-use bioprocessing market in the coming years:

• Advancements in materials science: The development of new materials with improved properties will lead to the development of more robust and efficient single-use systems.
• Integration of bioprocessing technologies: Single-use systems are becoming increasingly integrated with other bioprocessing technologies, such as sensors and automation systems. This will allow for more efficient and automated bioprocessing workflows.
• Expansion into new applications: Single-use bioprocessing is being increasingly used for a wider range of applications, such as gene therapy and cell therapy.

The single-use bioprocessing market is expected to continue to grow at a significant rate in the coming years. These trends are driven by the increasing demand for biopharmaceuticals, the need for faster and more efficient bioprocessing, and the focus on sustainability.

Immediate Delivery Available, Get Full Access@

https://www.novaoneadvisor.com/report/checkout/5765

Product Insights

The simple & peripheral elements segment recorded the largest market share of 49.61% in 2023 due to continuous innovations in these products and increasing prominence of bioprocessing operations in overall manufacturing process. Tubing, filters, connectors, and transfer systems held a majority share within simple & peripheral elements as tubing and connectors are provided by most single-use suppliers in a compatible format with single-use bags, bioreactors, or other single-use bioprocessing apparatus. For instance, Thermo Fisher Scientific, Inc. offers customization options to add tubing and connectors to its bioprocessing container bags and other bioprocessing equipment.These factors are expected to drive the segment.

The apparatus & plants segment is projected to grow at a rapid CAGR over the forecast period due to its significant penetration in the bioprocessing space majorly driven by a variety of single-use bioreactors. For instance, single-use bioreactors are available from a working volume range of 15 mL and 250 mL, such as the Ambr 15 and 250 sold by Sartorius AG, to a working volume of 6000 L, such as the CSR 7500 SUB sold by ABEC. This allows the end-users to easily scale products right from the stage of clone selection and benchtop production to harvesting high-volume yields of biologics. As a result, the availability of a broad range of options for apparatus & plants for bioprocessing is anticipated to drive the segment.

Workflow Insights

The upstream bioprocessing segment held the largest market share in 2023. This can be attributed to the continuous developments and advancements in technologies for upstream bioprocessing. For instance, advanced products, such as Ambr 15 micro-bioreactor system by Sartorius AG, are offering high-throughput upstream process development as well as efficient cell culture processing and media & feed optimization with automated experimental setup and sampling. These solutions can reduce the time taken for upstream bioprocessing operations and are anticipated to boost segment growth.

The fermentation segment is expected to register significant CAGR over the forecast period. The growth can be attributed to the launch of several innovative fermentation offerings that provide optimum conditions for bioprocessing reactions. For instance, the HyPerforma Enhanced S.U.F by Thermo Fisher Scientific, Inc. delivers optimal oxygen mass transfers and temperature control to the culture by increasing the turbine impellers and cooling jacket surface areas, respectively. Furthermore, companies like Cytiva are also involved in bringing single-use fermentation solutions for their end-users, such as the Xcellerex XDR MO, a stirred tank system with powerful mixing, efficient temperature control, and high oxygen transfer capacities for microbial cell culture. Significant innovations like these are likely to aid in revenue generation in this segment.

End-use Insights

Biopharmaceutical manufacturers dominated the market and accounted for the highest share in 2023. An increase in the commercial success of biologics in recent years and a rise in contract manufacturing/research services have led to the high growth of the segment. CROs and CMOs can offer several benefits in bioprocessing operations, such as scalability, flexibility, decreased internal infrastructure requirements, and dedicated supply channels. These advantages are fueling the adoption of contract services and are anticipated to positively affect the industry growth in the near future.

Academic & clinical research institutes are expected to grow at the fastest CAGR during 2024-2033.The availability of benchtop scale bioprocessing equipment and technological progress in single-use systems has accelerated the adoption of such technologies in academic and research institutes. For instance, institutes like the NIBRT (National Institute for Bioprocessing Research), in Ireland offer contract research services for biologics, while also conducting workshops and training for single-use technologies. Furthermore, the involvement of academic institutes and scientific communities in developing new biologics, such as cell & gene therapies and vector production, is likely to increase the implementation of single-use systems due to its cost reduction and flexibility benefits.

Regional Insights

North America held the largest revenue share of more than 34.45% in 2023, which can be attributed to the presence of an established pharmaceutical and biomanufacturing industry in the region as well as a high extent of R&D activities. Similarly, the demand for single-use bioprocessing equipment is also driven by an increasing focus on vaccine production to aid in disease prevention measures in the region. Moreover, the presence of the Bio-process System Alliance (BPSA) in North America, which aims at advancing the adoption of single-use technologies, is expected to further drive the sales of disposable systems in the region.

The Asia Pacific region is expected to grow at the fastest rate over the forecast period. The region’s growing bioprocessing market has resulted in multiple investments from several global companies. These investments assist in serving the key companies to create a regional presence and take advantage of the untapped avenues. Furthermore, the increasing interest of contract service providers to develop their base in the Asia Pacific, coupled with the trend of implementation of disposables in CMOs, acts as a catalyst for continued investments by local as well as global companies. For instance, in September 2021, Singapore witnessed the expansion of Lonza’s drug development facility. The CDMO enhanced its capacity to support the growing manufacturing needs in the region.

In China, the expansion of biopharmaceuticals market is driving the single-use bioprocessing market. Several international companies have expanded their manufacturing footprint in this region by forming mutually beneficial partnerships with China-based entities. Moreover, the primary focus of the country is on the development of affordable biosimilars of Western novel biotherapeutics for its domestic market, which is anticipated to positively influence market growth in the coming years.

Recent Developments

• In January 2024, CDMO AGC Biologics announced a growth strategy to develop pharmaceutical manufacturing capabilities in the Asia region through the expansion of their mammalian cell culture, mRNA and cell therapy facility in Japan. This development is aimed to support the global demand for biologics and advanced therapy medicinal products.
• In September 2023, Getinge launched a single-use bioreactor named the AppliFlex ST GMP. The new product is available in different sizes and provides a comprehensive cGMP manufacturing solution for mRNA production and cell and gene therapies.
• In April 2023, Merck KGaA launched Ultimus, a single-use process container film, to provide superior strength & leak resistance for single-use assemblies.
• In April 2023, Cytiva introduced the X-platform bioreactors that simplifies the upstream bioprocessing operations for the production of monoclonal antibodies (mAbs), protein-based drugs and cell and gene therapies.

Browse More Insights:

• Cell And Gene Therapy CDMO Market: The global Cell And Gene Therapy CDMO market size was estimated at USD 5.90 billion in 2023 and is projected to hit around USD 69.11 billion by 2033, growing at a CAGR of 27.9% during the forecast period from 2024 to 2033.
• Biopharmaceuticals Contract Manufacturing Market: The global biopharmaceuticals contract manufacturing market size was estimated at USD 19.89 billion in 2023 and is projected to hit around USD 33.65 billion by 2033, growing at a CAGR of 5.4% during the forecast period from 2024 to 2033.
• Single Cell Genome Sequencing Market: The global single cell genome sequencing market size was estimated at USD 2.85 billion in 2022 and is expected to surpass around USD 12.79 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 16.2% during the forecast period 2023 to 2032.
• Biotechnology Market : The global biotechnology market size was estimated at USD 1.54 Trillion in 2023 and is projected to hit around USD 5.68 Trillion by 2033, growing at a CAGR of 13.95% during the forecast period from 2024 to 2033.
• Oncology Clinical Trials Market : The global oncology clinical trials market size reached USD 13.19 billion in 2023 and is projected to hit around USD 22.11 billion by 2033, expanding at a CAGR of 5.3% during the forecast period from 2024 to 2033.
• Cell And Gene Therapy Manufacturing Market : The global cell and gene therapy manufacturing market size was estimated at USD 9.95 billion in 2023 and is projected to hit around USD 106.03 billion by 2033, growing at a CAGR of 26.7% during the forecast period from 2024 to 2033.

Key Single-use Bioprocessing Companies:

The following are the leading companies in the single-use bioprocessing market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these single-use bioprocessing companies are analyzed to map the supply network.

• Sartorius AG
• Danaher
• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Avantor, Inc.
• Eppendorf SE
• Corning Incorporated
• Lonza
• PBS Biotech, Inc.
• Meissner Filtration Products, Inc.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Single-use Bioprocessing market.

By Product

• Simple & Peripheral Elements
  • • Tubing, Filters, Connectors, & Transfer Systems
    • Bags
    • Sampling Systems
    • Probes & Sensors
      • pH Sensor
      • Oxygen Sensor
      • Pressure Sensors
      • Temperature Sensors
      • Conductivity Sensors
      • Flow Sensors
      • Others
    • Others
• Apparatus & Plants
  • Bioreactors
    • Upto 1000L
    • Above 1000L to 2000L
    • Above 2000L
  • Mixing, Storage, & Filling Systems
  • Filtration System
  • Chromatography Systems
  • Pumps
  • Others
• Work Equipment
  • Cell Culture System
  • Syringes
  • Others

By Workflow

• Upstream Bioprocessing
• Fermentation
• Downstream Bioprocessing

By By End-use

• Biopharmaceutical Manufacturers
  • CMOs & CROs
  • In-house Manufacturers
• Academic & Clinical Research Institutes

By Region

• North America
• Europe
• Asia-Pacific
• Latin America

Immediate Delivery Available | Buy This Premium Research

https://www.novaoneadvisor.com/report/checkout/5765

Call: USA: +1 650 460 3308 | IND: +91 87933 22019 |Europe: +44 2080772818

Email: sales@novaoneadvisor.com